查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370967

限制性內切酶市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、按應用、最終用戶、地區和競爭細分

Restriction Endonuclease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球限制性內切酶市場價值為 3.7076 億美元，預計在整個預測期內將呈現強勁成長，年複合成長率 (CAGR) 為 6.53%，預計到 2028 年將達到 5.3468 億美元。在稱為限制性位點的特定辨識核苷酸序列處切割DNA 的酵素。這些源自細菌的酵素在研究和商業領域都有應用。限制性內切酶根據其結構和切割特徵分為四種類型。這些酵素在分子生物學和遺傳學研究中發揮關鍵作用，能夠透過靶向特定位點來精確操作 DNA。它們的重要性在 DNA 克隆、基因編輯、基因工程和 DNA 分析中尤其顯著。

主要市場促進因素

增加資金

市場概況
預測期 2024-2028
2022 年市場規模 37076萬美元
2028 年市場規模 5.3468億美元
2023-2028 年年複合成長率 6.53%
成長最快的細分市場 醫院
最大的市場 北美洲

生物技術和製藥公司的資金和投資的注入正在顯著塑造全球限制性內切酶產品 (REP) 市場。這些酵素在限制性消化、克隆和測序等應用中的廣泛應用也促進了市場成長。資金的增加使研究人員能夠開展綜合研究項目，包括遺傳分析、基因編輯和 DNA 操作，推動了對限制性內切酶的需求。此外，增加的資金支持大規模基因組研究，包括全基因組關聯研究（GWAS）和全基因組定序項目，刺激了對用於資料分析和驗證的限制性內切酶的需求。 CRISPR-Cas9等依賴於限制性內切酶的基因編輯技術的開發和最佳化受益於資金的增加，從而增加了對這些酶的需求。

增加研發項目

生物技術和分子生物學的進步導致限制性內切酶新應用的發現。這些酵素在 DNA 克隆、基因編輯和基因工程等技術中發揮關鍵作用。隨著這些領域的發展，對促進 DNA 操作和修飾的限制性內切酶的需求不斷增加。隨著研究人員開發新的基因編輯技術或改進現有技術，對具有獨特識別序列或增強特異性的限制性內切酶的需求預計將會成長。限制性內切酶在生物分子研究中也發揮至關重要的作用，需要精確操作遺傳物質。該領域研究的擴展可以進一步推動對這些酶的需求。

老年人口增加

全球老年人口的成長預計將推動醫學研究、診斷和個人化醫療領域對限制性內切酶的需求。隨著人們越來越關注與年齡相關疾病的遺傳基礎，限制性內切酶成為 DNA 分析、基因定序和基因分型不可或缺的工具。需要根據其遺傳特徵進行個人化藥物治療的老年患者數量的增加預計將推動藥物基因組學研究中對限制性內切酶的需求。

慢性病病例不斷增加

具有遺傳成分的主要慢性疾病的病例不斷增加，導致基因研究、診斷和治療干涉措施的加強。限制性內切酶對於 DNA 分析和基因分型至關重要，使研究人員能夠識別與這些疾病相關的遺傳變異。人們越來越關注了解慢性疾病的遺傳基礎，預計將推動對這些酵素的需求。

主要市場挑戰

生產成本高

限制性內切酶的生產涉及複雜的過程，包括發酵、純化和品質控制。這些過程是資源密集的，需要專門的設備和專業知識。相關成本導致限制酶產品價格上漲，可能會阻礙預算有限的研究人員和實驗室採用它們。

缺乏嚴格的品質管制

在整個生產過程中保持嚴格的品質控制措施對於確保限制性酵素產品的一致性和可靠性至關重要。批次之間的差異可能導致實驗結果不可靠，浪費時間和資源。透明和全面的品質保證實踐可以在產品一致性和性能方面向研究人員灌輸信任。

主要市場趨勢

不斷崛起的創新技術

DNA 定序和基因表現等新穎方法的採用正在為全球限制性內切核酸酶產品市場的製造商和利害關係人帶來成長機會。 DNA 定序技術，包括下一代定序，徹底改變了基因組學研究。限制性內切酶在製備用於定序的 DNA 樣本、支持基因組學研究和實現個人化醫療方法方面發揮著至關重要的作用。

不斷增加的政府舉措

支持研究活動的政府措施預計將推動市場成長。政府在基因組學、個人化醫療、基因編輯和生物技術等領域的資助可以導致依賴限制性內切酶的研究計畫的擴展。這些措施可以塑造研究方向和技術發展，影響對限制性內切酶等基本研究工具的需求。

細分市場洞察

類型洞察

在限制性內切酶的類型中，I 型酶切由於其在具有挑戰性的目標和較長序列上切割 DNA 的特異性，佔據了最大的市場收入佔有率。

最終使用者見解

製藥和生物技術公司在限制性內切酶產品市場的最終用戶領域佔有重要地位，預計將大幅成長。製藥公司對基因療法和限制性內切酶產品應用的投資預計將推動市場擴張。這些酵素使研究人員能夠研究疾病的遺傳基礎、發現潛在的藥物標靶、開發治療藥物並推進個人化醫療方法。

區域洞察

由於傑出參與者的存在和研究活動的進步，北美在限制性內切酶產品市場上處於領先地位。併購有助於市場成長。在生物技術和製藥公司、私人和政府研究組織以及消費者對技術進步的認知不斷提高的推動下，亞太地區正在經歷巨大的市場成長。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球限制性內切核酸酶市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（I 型、II 型、III 型和 IV 型）
    • 按應用（基因工程、DNA 作圖、基因定序等）
    • 按最終用戶（製藥和生物技術公司、學術研究機構等）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美限制性內切核酸酶市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲限制性內切核酸酶市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區限制性內切酶市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲限制性內切核酸酶市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲限制性內切市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非限制性內切酶
    • 沙烏地阿拉伯限制性內切酶
    • 阿拉伯聯合大公國限制性內切酶

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球限制性內切核酸酶市場：SWOT 分析

第14章：競爭格局

  • 商業概覽
  • 服務產品
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific Inc.
    • Affymetrix, Inc.
    • Illumina, Inc.
    • Enzymatics, Inc.
    • QIAGEN NV
    • New England Biolabs, Inc.
    • Sigma-Aldrich Co. LLC.
    • Roche, Ltd.
    • Takara Bio, Inc

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 4638

The Global Restriction Endonuclease Market was valued at USD 370.76 Million in 2022 and is expected to exhibit robust growth throughout the forecast period, with a Compound Annual Growth Rate (CAGR) of 6.53% and expected to reach USD 534.68 Million through 2028. Restriction endonucleases are enzymes that cleave DNA at specific recognition nucleotide sequences known as restriction sites. These enzymes, derived from bacteria, find application in both research and commercial contexts. Restriction enzymes are classified into four types based on their structure and cleavage characteristics. These enzymes play a pivotal role in molecular biology and genetic research, enabling precise manipulation of DNA by targeting specific sites. Their significance is particularly notable in DNA cloning, gene editing, genetic engineering, and DNA analysis.

Key Market Drivers

Increasing Funding

Market Overview
Forecast Period2024-2028
Market Size 2022USD 370.76 Million
Market Size 2028USD 534.68 Million
CAGR 2023-20286.53%
Fastest Growing SegmentHospitals
Largest MarketNorth America

The infusion of funding and investments from biotechnology and pharmaceutical companies is significantly shaping the global restriction endonucleases products (REP) market. The expanding utilization of these enzymes for applications such as restriction digestion, cloning, and sequencing is also fostering market growth. Enhanced funding allows researchers to undertake comprehensive research projects, including genetic analysis, gene editing, and DNA manipulation, driving the demand for restriction endonucleases. Moreover, increased funding supports large-scale genomic studies, including genome-wide association studies (GWAS) and whole-genome sequencing projects, fueling the demand for restriction endonucleases for data analysis and validation. The development and optimization of gene editing technologies like CRISPR-Cas9, which rely on restriction endonucleases, benefit from increased funding, boosting the demand for these enzymes.

Increasing Research and Development Projects

Advancements in biotechnology and molecular biology lead to the discovery of novel applications for restriction endonucleases. These enzymes play a pivotal role in techniques such as DNA cloning, gene editing, and genetic engineering. As these fields evolve, the demand for restriction endonucleases to facilitate DNA manipulation and modification is on the rise. As researchers develop new gene editing techniques or improve existing ones, the demand for restriction endonucleases with unique recognition sequences or enhanced specificity is expected to grow. Restriction endonucleases also play a vital role in studying biomolecules, requiring precise manipulation of genetic material. The expansion of research in this domain can further drive the demand for these enzymes.

Rising Geriatric Population

The growing global geriatric population is expected to drive demand for restriction endonucleases in medical research, diagnostics, and personalized medicine. With an increasing focus on understanding the genetic basis of age-related diseases, restriction endonucleases become indispensable tools for DNA analysis, gene sequencing, and genotyping. The rise in geriatric patients requiring personalized drug regimens aligned with their genetic profiles is expected to drive demand for restriction endonucleases in pharmacogenomic studies.

Increasing Instances of Chronic Diseases

The growing instances of major chronic diseases with genetic components are leading to intensified genetic research, diagnostics, and therapeutic interventions. Restriction endonucleases are vital for DNA analysis and genotyping, allowing researchers to identify genetic variations associated with these diseases. This growing focus on understanding the genetic underpinnings of chronic diseases is expected to drive demand for these enzymes.

Key Market Challenges

High Cost of Production

The production of restriction endonucleases involves complex processes, including fermentation, purification, and quality control. These processes are resource-intensive and demand specialized equipment and expertise. The associated costs contribute to higher prices for restriction enzyme products, potentially hindering their adoption by researchers and laboratories with limited budgets.

Lack of Stringent Quality Control

Maintaining stringent quality control measures throughout the production process is essential to ensure consistency and reliability of restriction enzyme products. Variability between batches can lead to unreliable experimental results, wasting time and resources. Transparent and comprehensive quality assurance practices can instill trust in researchers regarding product consistency and performance.

Key Market Trends

Rising Innovative Techniques

The adoption of novel methodologies like DNA sequencing and gene expression is driving growth opportunities for manufacturers and stakeholders in the global restriction endonucleases products market. DNA sequencing technologies, including next-generation sequencing, have revolutionized genomics research. Restriction endonucleases play a crucial role in preparing DNA samples for sequencing, supporting genomics research and enabling personalized medicine approaches.

Rising Government Initiatives

Government initiatives supporting research activities are expected to drive market growth. Government funding in areas like genomics, personalized medicine, gene editing, and biotechnology can lead to expanded research projects relying on restriction endonucleases. These initiatives can shape research directions and technological developments, influencing the demand for essential research tools like restriction endonucleases.

Segmental Insights

Type Insights

Among the types of restriction enzymes, the type I segment holds the largest market revenue share due to its specificity in cleaving DNA at challenging targets and longer sequences.

End User Insights

Pharmaceutical & Biotechnology Companies have a significant presence in the end-user segment of the Restriction Endonucleases Products market and are projected to experience substantial growth. The investment by pharmaceutical companies in gene therapies and applications of Restriction Endonucleases Products is expected to drive market expansion. These enzymes enable researchers to study the genetic basis of diseases, discover potential drug targets, develop therapeutic agents, and advance personalized medicine approaches.

Regional Insights

North America leads the Restriction Endonucleases Products Market, attributed to the presence of prominent players and advancements in research activities. Mergers and acquisitions contribute to market growth. Asia Pacific is experiencing substantial market growth, driven by biotechnology and pharmaceutical companies, private and government research organizations, and increasing consumer awareness of technological advancements.

Key Market Players

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Affymetrix, Inc.
  • Illumina, Inc.
  • Enzymatics, Inc.
  • QIAGEN N.V.
  • New England Biolabs, Inc.
  • Sigma-Aldrich Co. LLC.
  • Roche, Ltd.
  • Takara Bio, Inc.

Report Scope:

In this report, the Global Restriction Endonuclease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Restriction Endonuclease Market, By Type:

  • Type I
  • Type II
  • Type III
  • Type IV

Restriction Endonuclease Market, By Application:

  • Genetic Engineering
  • DNA Mapping
  • Gene Sequencing
  • Others

Restriction Endonuclease Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institutes
  • Others

Restriction Endonuclease Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Restriction Endonuclease Market.

Available Customizations:

  • Global Restriction Endonuclease market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Restriction Endonuclease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Type I, Type II, Type III, and Type IV)
    • 5.2.2. By Application (Genetic Engineering, DNA Mapping, Gene Sequencing, and Others)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Restriction Endonuclease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Restriction Endonuclease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Restriction Endonuclease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Restriction Endonuclease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Restriction Endonuclease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Restriction Endonuclease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Restriction Endonuclease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Restriction Endonuclease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Restriction Endonuclease Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Restriction Endonuclease Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Restriction Endonuclease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Restriction Endonuclease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Restriction Endonuclease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Restriction Endonuclease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Restriction Endonuclease Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Restriction Endonuclease Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Restriction Endonuclease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Restriction Endonuclease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Restriction Endonuclease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Restriction Endonuclease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Restriction Endonuclease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Restriction Endonuclease Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Restriction Endonuclease Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Restriction Endonuclease Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Restriction Endonuclease Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Services Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Agilent Technologies, Inc.
    • 14.5.2. Thermo Fisher Scientific Inc.
    • 14.5.3. Affymetrix, Inc.
    • 14.5.4. Illumina, Inc.
    • 14.5.5. Enzymatics, Inc.
    • 14.5.6. QIAGEN N.V.
    • 14.5.7. New England Biolabs, Inc.
    • 14.5.8. Sigma-Aldrich Co. LLC.
    • 14.5.9. Roche, Ltd.
    • 14.5.10. Takara Bio, Inc

15. Strategic Recommendations

16. About Us & Disclaimer